Directorio de personas
Anabel Sorolla Bardaji

Anabel Sorolla Bardaji

Grado: Doctor/a


asorolla(ELIMINAR)@irblleida.cat

ResearcherID: http://www.researcherid.com/rid/E-2546-2012

Publicaciones

  • Tonks ID; Mukhopadhyay P; Schroder WA; Sorolla A; Mould AW; Handoko HY; Ferguson B; Muller HK; Keith P; Hayward NK; Walker GJ; Kay GF

    Melanocyte transformation requires complete loss of all pocket protein function via a mechanism that mitigates the need for MAPK pathway activation.

    ONCOGENE 36 3789-3795. .

    [doi:10.1038/onc.2016.511]

  • Garcia-Bloj B; Moses C; Sgro A; Plani-Lam J; Arooj M; Duffy C; Thiruvengadam S; Sorolla A; Rashwan R; Mancera RL; Leisewitz A; Swift-Scanlan T; Corvalan AH; Blancafort P

    Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system.

    Oncotarget 7 60535-60554. .

    [doi:10.18632/oncotarget.11142]

  • Sorolla A; Ho D; Wang E; Evans CW; Ormonde CF; Rashwan R; Singh R; Iyer KS; Blancafort P

    Sensitizing basal-like breast cancer to chemotherapy using nanoparticles conjugated with interference peptide.

    Nanoscale 8 9343-9353. .

    [doi:10.1039/c5nr08331a]

  • Senft D; Sorolla A; Dewing A; Claps G; Lau E; Walker GJ; Ronai ZA

    ATF2 alters melanocyte response and macrophage recruitment in UV-irradiated neonatal mouse skin.

    PIGMENT CELL & MELANOMA RESEARCH 28 481-484. .

    [doi:10.1111/pcmr.12382]

  • Sorolla A; Tallack MR; Oey H; Harten SK; Daxinger LC; Magor GW; Combes AN; Ilsley M; Whitelaw E; Perkins AC

    Identification of novel hypomorphic and null mutations in Klf1 derived from a genetic screen for modifiers of a-globin transgene variegation.

    GENOMICS 105 116-122. .

    [doi:10.1016/j.ygeno.2014.09.013]

  • Bergadà L; Yeramian A; Sorolla A; Matias-Guiu X; Dolcet X

    Antioxidants Impair Anti-Tumoral Effects of Vorinostat, but Not Anti-Neoplastic Effects of Vorinostat and Caspase-8 Downregulation

    PLOS ONE 9 -. .

    [doi:10.1371/journal.pone.0092764]

  • Bergadà L; Sorolla A; Yeramian A; Eritja N; Mirantes C; Matias-Guiu X; Dolcet X

    Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells

    MOLECULAR ONCOLOGY 7 763-775. .

    [doi:10.1016/j.molonc.2013.03.003]

  • Daxinger L; Harten SK; Oey H; Epp T; Isbel L; Huang E; Whitelaw N; Apedaile A; Sorolla A; Yong J; Bharti V; Sutton J; Ashe A; Pang Z; Wallace N; Gerhardt DJ; Blewitt ME; Jeddeloh JA; Whitelaw E

    An ENU mutagenesis screen identifies novel and known genes involved in epigenetic processes in the mouse.

    GENOME BIOLOGY 14 -. .

    [doi:10.1186/gb-2013-14-9-r96]

  • Sorolla, Anabel; Yeramian, Andree; Valls, Joan; Dolcet, Xavier; Bergada, Laura; Llombart-Cussac, Antoni; Maria Marti, Rosa; Matias-Guiu, Xavier

    Blockade of NF kappa B activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells

    MOLECULAR ONCOLOGY 6 530-541. .

    [doi:10.1016/j.molonc.2012.06.006]

  • MARTI LABORDA, ROSA MARIA; Sorolla A; Yeramian A

    New therapeutic targets in melanoma.

    ACTAS DERMO-SIFILIOGRAFICAS 103 579-590. .

    [doi:10.1016/j.ad.2011.08.009]

  • Das, A.; Pushparaj, C.; Bahi, N.; Sorolla, A.; Herreros, J.; Pamplona, R.; Vilella, R.; Matias-Guiu, X.; Marti, R. M.; Canti, C.

    Functional expression of voltage-gated calcium channels in human melanoma

    PIGMENT CELL & MELANOMA RESEARCH 25 200-212. .

    [doi:10.1111/j.1755-148X.2012.00978.x]

  • Yeramian, Andree; Sorolla, Anabel; Velasco, Ana; Santacana, Maria; Dolcet, Xavier; Valls, Joan; Abal, Leandre; Moreno, Sara; Egido, Ramon; Casanova, Josep M.; Puig, Susana; Vilella, Ramon; Llombart-Cussac, Antonio; Matias-Guiu, Xavier; Marti, Rosa M.

    Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway

    INTERNATIONAL JOURNAL OF CANCER 130 967-978. .

    [doi:10.1002/ijc.26096]

Proyectos

  • DEVELOPMENT OF PRECISION THERAPIES FOR TRIPLE NEGATIVE BREAST CANCERS BASED ON CRISPR/CAS9 RIBONUCLEOPROTEINS.
  • Development of precision therapies for triple negative breast cancer based on CRISPR/Cas12a ribonucleoproteins
  • Contrato Miguel Servet - Proyecto + RRHH
  • EXPRESION DE CANALES DE CALCIO DE TIPO T EN NEOPLASIAS MELANOCÍTICAS BENIGNAS Y MALIGNAS. EVALUACION DE SU APLICICABILIDAD CLINICA COMO DIANAS TERAPEUTICAS EN EL MELANOMA